Chondroitin sulfate (CS) is recommended by EULAR as a SYSADOA (Symptomatic Slow Acting Drug for OA) drug in Europe in the treatment of knee, hip and hand osteoarthritis. CS efficacy have been evaluated in clinical studies by using a very pure product having specific properties and physico-chemical characteristics as approved by the various National Institutes of Health.Food supplement/nutraceutical preparations in tablet or capsule containing CS are also available on the market. The amount and quality of CS from several of these preparations available on Czech Republic were determined. In order to quantify CS, two different analytical approaches were applied after their validation, specific and sensitive agarose-gel electrophoresis and SAX-HPLC determination of the constituent disaccharides after treatment with specific chondroitin lyases. The quantitative determinations were performed using a very high pure European Pharmacopeia CS reference standard having substantially the same properties as the food supplement CS samples.The CS content in food supplement products were found to conform to the label specifications only in four of the ten analyzed samples. Four of the food supplement preparations were found to contain approx. 0-1% CS in comparison with 47, 17, 12 and 6% declared on the label. Two products were found to have approx. 30-45% of the declared CS, and one preparation was found to contain approx. 2% hyaluronic acid. SAX-HPLC separation of unsaturated disaccharides for the nutraceutical CS was also used to evaluate its quality and the possible origin. The CS contained in eight food supplements resulted to be of bovine or porcine origin, one from cartilagineous fishes and in one case it was not possible to determine the origin due to a very low CS content.In conclusion, a multi-analytical approach was used in the direct quantitation and evaluation of the quality and the possible origin of CS contained in ten Czech Republic food supplement formulations. On the basis of these analytical results, the quality of these dietary supplements is poor and strict regulations for quality control should be mandatory in order to guarantee the manufacture of high quality products. Furthermore, specific and accurate analytical procedures should be enforced for the control of high quality products and applied by quality control laboratories to confirm the purity and label claim of CS in raw materials and nutraceuticals.

Hodnocení chondroitin sulfátu v potravinových doplňcích v České republice (evaluation of chondroitin sulfate in Czech Republic food supplements) / Volpi, Nicola; Maccari, Francesca. - In: FARMAKOTERAPIE. - ISSN 1801-1209. - STAMPA. - 4:(2008), pp. 418-421.

Hodnocení chondroitin sulfátu v potravinových doplňcích v České republice (evaluation of chondroitin sulfate in Czech Republic food supplements)

VOLPI, Nicola;MACCARI, Francesca
2008

Abstract

Chondroitin sulfate (CS) is recommended by EULAR as a SYSADOA (Symptomatic Slow Acting Drug for OA) drug in Europe in the treatment of knee, hip and hand osteoarthritis. CS efficacy have been evaluated in clinical studies by using a very pure product having specific properties and physico-chemical characteristics as approved by the various National Institutes of Health.Food supplement/nutraceutical preparations in tablet or capsule containing CS are also available on the market. The amount and quality of CS from several of these preparations available on Czech Republic were determined. In order to quantify CS, two different analytical approaches were applied after their validation, specific and sensitive agarose-gel electrophoresis and SAX-HPLC determination of the constituent disaccharides after treatment with specific chondroitin lyases. The quantitative determinations were performed using a very high pure European Pharmacopeia CS reference standard having substantially the same properties as the food supplement CS samples.The CS content in food supplement products were found to conform to the label specifications only in four of the ten analyzed samples. Four of the food supplement preparations were found to contain approx. 0-1% CS in comparison with 47, 17, 12 and 6% declared on the label. Two products were found to have approx. 30-45% of the declared CS, and one preparation was found to contain approx. 2% hyaluronic acid. SAX-HPLC separation of unsaturated disaccharides for the nutraceutical CS was also used to evaluate its quality and the possible origin. The CS contained in eight food supplements resulted to be of bovine or porcine origin, one from cartilagineous fishes and in one case it was not possible to determine the origin due to a very low CS content.In conclusion, a multi-analytical approach was used in the direct quantitation and evaluation of the quality and the possible origin of CS contained in ten Czech Republic food supplement formulations. On the basis of these analytical results, the quality of these dietary supplements is poor and strict regulations for quality control should be mandatory in order to guarantee the manufacture of high quality products. Furthermore, specific and accurate analytical procedures should be enforced for the control of high quality products and applied by quality control laboratories to confirm the purity and label claim of CS in raw materials and nutraceuticals.
2008
4
418
421
Hodnocení chondroitin sulfátu v potravinových doplňcích v České republice (evaluation of chondroitin sulfate in Czech Republic food supplements) / Volpi, Nicola; Maccari, Francesca. - In: FARMAKOTERAPIE. - ISSN 1801-1209. - STAMPA. - 4:(2008), pp. 418-421.
Volpi, Nicola; Maccari, Francesca
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/612639
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact